BR112021012065A2 - Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia - Google Patents
Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiiaInfo
- Publication number
- BR112021012065A2 BR112021012065A2 BR112021012065A BR112021012065A BR112021012065A2 BR 112021012065 A2 BR112021012065 A2 BR 112021012065A2 BR 112021012065 A BR112021012065 A BR 112021012065A BR 112021012065 A BR112021012065 A BR 112021012065A BR 112021012065 A2 BR112021012065 A2 BR 112021012065A2
- Authority
- BR
- Brazil
- Prior art keywords
- bispecific antibody
- antibody
- hemophilia
- fixa
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 10
- 208000031220 Hemophilia Diseases 0.000 title abstract 5
- 208000009292 Hemophilia A Diseases 0.000 title abstract 5
- 238000000338 in vitro Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000032843 Hemorrhage Diseases 0.000 title abstract 3
- 230000004913 activation Effects 0.000 title abstract 3
- 230000000740 bleeding effect Effects 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia. trata-se de moléculas de ligação a antígeno biespecífico (por exemplo, anticorpos) que se ligam a fatores de coagulação sanquínea, fator ixa (fixa) e fator x (fx), e aumentam a ativação de fx a fxa catalisada por fixa. trata-se também do uso de moléculas de ligação a antígeno biespecífico para controlar o sangramento, substituindo-se o cofator natural fviiia, que é deficiente em pacientes com hemofilia a.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820977.5A GB201820977D0 (en) | 2018-12-21 | 2018-12-21 | Fixaxfx bispecific antibody with commomn light chain |
| GBGB1906816.2A GB201906816D0 (en) | 2019-05-15 | 2019-05-15 | FIXaxFX bispecific antibody with common light chain |
| GBGB1908190.0A GB201908190D0 (en) | 2019-06-07 | 2019-06-07 | Fixaxfx bispecific antibody with common light chain |
| PCT/EP2019/086808 WO2020128049A1 (en) | 2018-12-21 | 2019-12-20 | Fixaxfx bispecific antibody with common light chain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021012065A2 true BR112021012065A2 (pt) | 2021-12-07 |
Family
ID=69167786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021012065A BR112021012065A2 (pt) | 2018-12-21 | 2019-12-20 | Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20220064327A1 (pt) |
| EP (2) | EP3723858B1 (pt) |
| JP (1) | JP2022515770A (pt) |
| KR (1) | KR20210118085A (pt) |
| CN (1) | CN113453757A (pt) |
| BR (1) | BR112021012065A2 (pt) |
| CA (1) | CA3123177A1 (pt) |
| DK (1) | DK3723858T3 (pt) |
| ES (1) | ES2901683T3 (pt) |
| HR (1) | HRP20220088T1 (pt) |
| HU (1) | HUE057634T2 (pt) |
| LT (1) | LT3723858T (pt) |
| PL (1) | PL3723858T3 (pt) |
| PT (1) | PT3723858T (pt) |
| RS (1) | RS62848B1 (pt) |
| SI (1) | SI3723858T1 (pt) |
| TW (1) | TWI772724B (pt) |
| WO (1) | WO2020128049A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| PL3723858T3 (pl) | 2018-12-21 | 2022-03-07 | Kymab Limited | Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| WO2023147574A2 (en) * | 2022-01-31 | 2023-08-03 | The Children's Hospital Of Philadelphia | Compositions and methods for treating factor ix deficiency |
| KR20240007881A (ko) | 2022-07-08 | 2024-01-17 | 노보 노르디스크 에이/에스 | FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| EP1693448A4 (en) | 2003-10-14 | 2008-03-05 | Chugai Pharmaceutical Co Ltd | DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| SI1876236T1 (sl) | 2005-04-08 | 2014-11-28 | Chugai Seiyaku Kabushiki Kaisha | Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi |
| BRPI0612734A2 (pt) | 2005-07-05 | 2010-11-30 | Glaxo Group Ltd | anticorpo monoclonal, composição farmacêutica, métodos de promoção de brotamento axonal, e de produção de um anticorpo anti-nogo, e, uso de um anticorpo anti-nogo |
| CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
| EP3916011A1 (en) | 2009-06-26 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
| PH12016502073A1 (en) * | 2010-11-17 | 2018-01-29 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| JP6393255B2 (ja) | 2012-04-20 | 2018-09-19 | メルス ナムローゼ フェンノートシャップ | ヘテロ二量体のＩｇＧ様分子を生産する方法、ヘテロ二量体のＩｇＧ様分子、ヘテロ二量体の抗体、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物 |
| US10066019B2 (en) | 2012-10-12 | 2018-09-04 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| EP3065768B1 (en) | 2013-11-04 | 2020-09-23 | The Regents of the University of California | Composition for use in treatment or prevention of conditions associated with bleeding or hypocoagulationcompostion |
| WO2015103072A1 (en) | 2013-12-30 | 2015-07-09 | Epimab Biotherapeutics | Fabs-in-tandem immunoglobulin and uses thereof |
| TW201625299A (zh) | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| JP6698102B2 (ja) | 2015-04-17 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 凝固因子と多重特異的抗体を用いた併用療法 |
| JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物 |
| WO2017072310A1 (en) | 2015-10-30 | 2017-05-04 | Medimmune Limited | Prevention of n-terminal truncation in igg light chains |
| WO2017110980A1 (ja) | 2015-12-25 | 2017-06-29 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| CU24613B1 (es) | 2016-02-06 | 2022-07-08 | Epimab Biotherapeutics Inc | Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr |
| KR102481704B1 (ko) | 2016-05-16 | 2022-12-27 | 다케다 파머수티컬 컴패니 리미티드 | 항-인자 ix 파두아 항체 |
| CA3027018A1 (en) * | 2016-07-29 | 2018-02-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| KR102560808B1 (ko) | 2016-09-06 | 2023-07-27 | 추가이 세이야쿠 가부시키가이샤 | 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법 |
| MX2019005772A (es) * | 2016-11-23 | 2019-10-02 | Bioverativ Therapeutics Inc | Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x. |
| BR112019015611A2 (pt) | 2017-02-01 | 2020-03-17 | Novo Nordisk A/S | Anticorpos pró-coagulantes |
| US20210284715A1 (en) | 2017-02-06 | 2021-09-16 | Applied Stemcell, Inc. | Coagulation factor viii mimetic protein and uses thereof |
| EP3621643A4 (en) | 2017-05-11 | 2021-07-21 | Atreca, Inc. | ANTIBODY ANTI-MALARIA BOUND WITH CIRCUMSPOROZOID PROTEIN |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| TW201936634A (zh) | 2017-09-29 | 2019-09-16 | 日商中外製藥股份有限公司 | 具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑 |
| MA50893A (fr) | 2017-11-15 | 2020-09-23 | Novo Nordisk As | Liants de facteur x renforçant l'activation fx |
| PL3723858T3 (pl) * | 2018-12-21 | 2022-03-07 | Kymab Limited | Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim |
-
2019
- 2019-12-20 PL PL19836806T patent/PL3723858T3/pl unknown
- 2019-12-20 DK DK19836806.0T patent/DK3723858T3/da active
- 2019-12-20 ES ES19836806T patent/ES2901683T3/es active Active
- 2019-12-20 LT LTEPPCT/EP2019/086808T patent/LT3723858T/lt unknown
- 2019-12-20 PT PT198368060T patent/PT3723858T/pt unknown
- 2019-12-20 CN CN201980091786.3A patent/CN113453757A/zh active Pending
- 2019-12-20 HR HRP20220088TT patent/HRP20220088T1/hr unknown
- 2019-12-20 TW TW108146911A patent/TWI772724B/zh active
- 2019-12-20 HU HUE19836806A patent/HUE057634T2/hu unknown
- 2019-12-20 US US17/311,595 patent/US20220064327A1/en active Pending
- 2019-12-20 EP EP19836806.0A patent/EP3723858B1/en active Active
- 2019-12-20 EP EP21204339.2A patent/EP4015538A1/en active Pending
- 2019-12-20 US US16/722,452 patent/US10815308B2/en active Active
- 2019-12-20 BR BR112021012065A patent/BR112021012065A2/pt not_active Application Discontinuation
- 2019-12-20 SI SI201930150T patent/SI3723858T1/sl unknown
- 2019-12-20 CA CA3123177A patent/CA3123177A1/en active Pending
- 2019-12-20 JP JP2021535950A patent/JP2022515770A/ja active Pending
- 2019-12-20 KR KR1020217022770A patent/KR20210118085A/ko unknown
- 2019-12-20 WO PCT/EP2019/086808 patent/WO2020128049A1/en unknown
- 2019-12-20 RS RS20220069A patent/RS62848B1/sr unknown
-
2020
- 2020-10-06 US US17/063,905 patent/US11976135B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10815308B2 (en) | 2020-10-27 |
| PL3723858T3 (pl) | 2022-03-07 |
| HUE057634T2 (hu) | 2022-05-28 |
| CN113453757A (zh) | 2021-09-28 |
| HRP20220088T1 (hr) | 2022-04-15 |
| PT3723858T (pt) | 2022-02-02 |
| ES2901683T3 (es) | 2022-03-23 |
| US20210101997A1 (en) | 2021-04-08 |
| EP4015538A1 (en) | 2022-06-22 |
| RS62848B1 (sr) | 2022-02-28 |
| CA3123177A1 (en) | 2020-06-25 |
| US20220064327A1 (en) | 2022-03-03 |
| SI3723858T1 (sl) | 2022-04-29 |
| TW202039584A (zh) | 2020-11-01 |
| US20200199250A1 (en) | 2020-06-25 |
| KR20210118085A (ko) | 2021-09-29 |
| TWI772724B (zh) | 2022-08-01 |
| EP3723858A1 (en) | 2020-10-21 |
| US11976135B2 (en) | 2024-05-07 |
| WO2020128049A1 (en) | 2020-06-25 |
| JP2022515770A (ja) | 2022-02-22 |
| EP3723858B1 (en) | 2021-10-27 |
| LT3723858T (lt) | 2022-02-10 |
| DK3723858T3 (da) | 2022-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021012065A2 (pt) | Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia | |
| Yu et al. | FGF-dependent metabolic control of vascular development | |
| BR112019010349A2 (pt) | Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores | |
| Shih et al. | Matrix stiffness regulation of integrin‐mediated mechanotransduction during osteogenic differentiation of human mesenchymal stem cells | |
| Lee et al. | Melatonin enhances the human mesenchymal stem cells motility via melatonin receptor 2 coupling with Gαq in skin wound healing | |
| Chen et al. | Dedifferentiation of lineage-committed cells by a small molecule | |
| Ha et al. | Stem Cell! | |
| Li et al. | The histone methyltransferase SETD1A regulates thrombomodulin transcription in vascular endothelial cells | |
| Tarjus et al. | The endothelial αENaC contributes to vascular endothelial function in vivo | |
| Donkor et al. | Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa | |
| BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
| Bai et al. | A far-upstream AP-1/Smad binding box regulates human NOX4 promoter activation by transforming growth factor-β | |
| Muraro et al. | Ex-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments | |
| EA201491235A1 (ru) | Варианты полипептидов fc-pol с улучшенным связыванием неонатального рецептора fc | |
| Walsh et al. | RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch | |
| CO6460768A2 (es) | Anticuerpos específicos para dkk-1 y sus usos | |
| Jung et al. | Oleic acid enhances the motility of umbilical cord blood derived mesenchymal stem cells through EphB2-dependent F-actin formation | |
| Tang et al. | PARP9 is overexpressed in human breast cancer and promotes cancer cell migration | |
| Yamanegi et al. | Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells | |
| Masumura et al. | Btg2 is a negative regulator of cardiomyocyte hypertrophy through a decrease in cytosolic RNA | |
| ATE532868T1 (de) | Apoptose induzierende positivkontrolle für expressionsmodulationsexperimente | |
| BR112021024553A2 (pt) | Molécula de ligação específica para cd73 e uso de molécula de ligação | |
| BR112019010034A2 (pt) | fator viii alvejado de hemácia e método de uso do mesmo | |
| Zhang et al. | LncRNA XIST facilitates S1P-mediated osteoclast differentiation via interacting with FUS | |
| Teodorescu et al. | Transforming growth factor β‐mediated micromechanics modulates disease progression in primary myelofibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |